Provided by Tiger Trade Technology Pte. Ltd.

Aquestive Therapeutics Inc.

4.55
+0.11002.48%
Post-market: 4.54-0.0100-0.22%19:39 EDT
Volume:2.27M
Turnover:10.26M
Market Cap:570.80M
PE:-6.99
High:4.60
Open:4.53
Low:4.43
Close:4.44
52wk High:7.55
52wk Low:2.93
Shares:125.45M
Float Shares:115.00M
Volume Ratio:1.14
T/O Rate:1.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6512
EPS(LYR):-0.7836
ROE:148.50%
ROA:-29.20%
PB:-10.09
PE(LYR):-5.81

Loading ...

Aquestive Therapeutics appoints Daly to board of directors

TIPRANKS
·
Sep 29

Press Release: Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly

Dow Jones
·
Sep 29

Aquestive Therapeutics (AQST) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Sep 22

Aquestive Resubmits FDA NDA for Anaphylm After Human Factors, Confirmatory PK Studies

Reuters
·
Sep 17

Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (Dibutepinephrine) Sublingual Film

THOMSON REUTERS
·
Sep 17

Aquestive Therapeutics, - FDA to Determine Resubmission Classification and Review Timeline

THOMSON REUTERS
·
Sep 17

Aquestive Therapeutics CEO Daniel Barber Disposes of 25,000 Shares Worth $120,487.50

Reuters
·
Sep 17

Aquestive Therapeutics Chief Commercial Officer Sherry Korczynski Disposes of $45,675 in Common Shares

Reuters
·
Sep 11

Aquestive Therapeutics CEO Daniel Barber Disposes of 25,000 Common Shares Worth $107,168

Reuters
·
Aug 19

ARS Pharmaceuticals Q2 Neffy Revenue Rises as Epinephrine Market Share Doubles

Reuters
·
Aug 14

Analysts’ Top Healthcare Picks: Neurocrine (NBIX), Aquestive Therapeutics (AQST)

TIPRANKS
·
Aug 13

Aquestive Therapeutics (AQST) Stock Faces Cash Burn Questions As Anaphylm Nears Resubmission

Simply Wall St.
·
Aug 13

Aquestive Therapeutics Forecasts 2026 Revenue USD 46 Million-50 Million

Reuters
·
Aug 12

Aquestive Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Aquestive Therapeutics Q2 Revenue Beats on Suboxone Strength

Reuters
·
Aug 12

Aquestive Therapeutics, Inc. Q2 Revenue USD 13.819 Million Vs. IBES Estimate USD 11.4 Million

Reuters
·
Aug 12

Aquestive Therapeutics Inc: Full-Year 2026 Financial Guidance Remains Unchanged

THOMSON REUTERS
·
Aug 12

Aquestive Therapeutics: Confirms That Its Supply Chain Currently Remains Largely Unaffected by Both Implemented & Proposed Government Tariffs

THOMSON REUTERS
·
Aug 12

Aquestive Therapeutics, Inc. Q2 EPS USD -0.18

THOMSON REUTERS
·
Aug 12

Aquestive Therapeutics Inc: on Track to Begin Ex-U.S. Filings of Anaphylm in Q4 2026

THOMSON REUTERS
·
Aug 12